F Cremonini

Summary

Affiliation: Harvard University
Country: USA

Publications

  1. ncbi Randomised clinical trial: alosetron improves quality of life and reduces restriction of daily activities in women with severe diarrhoea-predominant IBS
    F Cremonini
    Division of Gastroenterology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA02215, USA
    Aliment Pharmacol Ther 36:437-48. 2012
  2. ncbi Evolving concepts in chronic constipation in Europe and elsewhere: not worlds apart
    F Cremonini
    Division of Gastroenterology, Beth Israel Deaconess Medical Center, Harvard Medical School, 330 Brookline Avenue, Boston, MA 02215, USA
    Neurogastroenterol Motil 23:693-6. 2011
  3. ncbi Rifaximin for the treatment of irritable bowel syndrome
    Filippo Cremonini
    Harvard Medical School, Center for Clinical and Translational research in Gastrointestinal Motility, Beth Israel Deaconess Medical Center, Division of Gastroenterology, 330 Brookline Avenue, Boston, MA 02215, USA
    Expert Opin Pharmacother 13:433-40. 2012
  4. ncbi Clinical trial: renzapride treatment of women with irritable bowel syndrome and constipation - a double-blind, randomized, placebo-controlled, study
    A J Lembo
    Division of Gastroenterology, Department of Medicine, Beth Israel Deaconess Medical Center BIDMC, Harvard Medical School, Boston, MA 02215, USA
    Aliment Pharmacol Ther 31:979-90. 2010
  5. ncbi Meta-analysis: the effects of placebo treatment on gastro-oesophageal reflux disease
    F Cremonini
    Beth Israel Deaconess Medical Center, Boston, MA, USA
    Aliment Pharmacol Ther 32:29-42. 2010
  6. ncbi Meta-analysis: probiotics in antibiotic-associated diarrhoea
    E J Videlock
    Beth Israel Deaconess Medical Center, Boston, MA, USA
    Aliment Pharmacol Ther 35:1355-69. 2012

Collaborators

Detail Information

Publications6

  1. ncbi Randomised clinical trial: alosetron improves quality of life and reduces restriction of daily activities in women with severe diarrhoea-predominant IBS
    F Cremonini
    Division of Gastroenterology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA02215, USA
    Aliment Pharmacol Ther 36:437-48. 2012
    ..Patients with irritable bowel syndrome with diarrhoea (IBS-D) experience restriction in daily activities and decreased health-related quality of life (QOL)...
  2. ncbi Evolving concepts in chronic constipation in Europe and elsewhere: not worlds apart
    F Cremonini
    Division of Gastroenterology, Beth Israel Deaconess Medical Center, Harvard Medical School, 330 Brookline Avenue, Boston, MA 02215, USA
    Neurogastroenterol Motil 23:693-6. 2011
    ....
  3. ncbi Rifaximin for the treatment of irritable bowel syndrome
    Filippo Cremonini
    Harvard Medical School, Center for Clinical and Translational research in Gastrointestinal Motility, Beth Israel Deaconess Medical Center, Division of Gastroenterology, 330 Brookline Avenue, Boston, MA 02215, USA
    Expert Opin Pharmacother 13:433-40. 2012
    ..Strategies for appropriate patient selection need to be further developed, and continued efficacy of rifaximin over repeated treatment courses needs to be better characterized...
  4. ncbi Clinical trial: renzapride treatment of women with irritable bowel syndrome and constipation - a double-blind, randomized, placebo-controlled, study
    A J Lembo
    Division of Gastroenterology, Department of Medicine, Beth Israel Deaconess Medical Center BIDMC, Harvard Medical School, Boston, MA 02215, USA
    Aliment Pharmacol Ther 31:979-90. 2010
    ..Renzapride, a 5-hydroxytryptamine type-4 (5-HT(4)) receptor agonist and 5-HT(3) receptor antagonist, has been proposed as a new treatment of irritable bowel syndrome with constipation (IBS-C)...
  5. ncbi Meta-analysis: the effects of placebo treatment on gastro-oesophageal reflux disease
    F Cremonini
    Beth Israel Deaconess Medical Center, Boston, MA, USA
    Aliment Pharmacol Ther 32:29-42. 2010
    ..Little is known about the determinants and the circumstances associated with placebo response in the treatment of gastro-oesophageal reflux disease (GERD)...
  6. ncbi Meta-analysis: probiotics in antibiotic-associated diarrhoea
    E J Videlock
    Beth Israel Deaconess Medical Center, Boston, MA, USA
    Aliment Pharmacol Ther 35:1355-69. 2012
    ..Diarrhoea is a common occurrence in association with antibiotic administration. Earlier studies and meta-analyses have suggested that probiotic administration reduces the incidence of antibiotic-associated diarrhoea (AAD)...